Zusammenfassung
Ein Parkinson-Syndrom ist eine progredient verlaufende Krankheit, die im Spät-stadium erhebliche Behinderungsgrade bewirken kann. Die prognostische Beurteilung eines individuellen Verlaufs ist schwierig, erfordert aber in jedem Fall zunächst eine exakte differenzialdiagnostische Einordnung. Die idiopathische Parkinsonkrankheit muss von anderen degenerativen Prozessen (ParkinsonPlus-Syndromen) abgegrenzt werden [8]. Diagnostische Kriterien für das Vorliegen einer idiopathischen Parkinsonkrankheit sind gut validiert (sog. Londonbrain-bank-Kriterien; siehe Tabelle 1). Auch für die häufigsten Parkinson-PlusSyndome (siehe Tabelle 2) liegen international akzeptierte Kriterien vor [29].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Gibb WR, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 51: 745–752
Gilman S, Low P, Quinn N (1998) Consensus statement on the diagnosis of multiple system atrophy. Clin Auton Res 8: 359–362
Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression, and mortality. Neurology 17: 427–442
Horowski R, Horowsk L, Vogel S, Poewe W, Kielhorn FW (1995) An essay on Wilhelm von Humboldt and the shaking palsy: first comprehensive description of Parkinson’s disease by a patient. Neurology 45: 565–568
Humboldt W von (1986) Briefe an eine Freundin. Lindner J (Hrsg) Verlag der Nation, Berlin
Jankovic J, Kapadia AS (2001) Funcional decline in Parkinson’s disease. Arch Neurol 58: 1611–1615
Kostic V, Przedborski S, Flaster E, Sternic N (1991) Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson’s disease. Neurology 41: 202–205
Lachenmayer L, Arning C, Reichmann H (2002) Frith-und Differenzialdiagnose der Parkinson-Syndrome. Nervenheilkunde 21: 38–45
Lakke JPWF (1996) Wilhelm von Humboldt and James Parkinson. An appraisal of observation and creativity. Parkinsonism and Related Disorders 2: 225–229
Leplow B (1998) Psychologische und psychosoziale Aspekte beim Parkinson-Syndrom. Psycho 24: 554–559
Litvan I, Agid Y, Caine D (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47: 1–9
Martinez-Martin P, Valldeoriola F, Tolosa E, Pilleri M, Molinuevo, JL, Rumia J, Ferrer E (2002) Bilateral subthalamic nucleus stimulation and quality of life in advanced Parkinson’s disease. Mov Disord 17: 372–377
McKeith IG, Galasko D, Kosaka K (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47: 1113–1124
McKeith IG, Perry EK, Perry RH (1999) Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Neurology 53: 902–905
Morrish P (2002) Is it time to abandon functional imaging in the study of neuroprotection? Mov Disord 17: 229–232
Muller J, Wenning GK, Jellinger K, McKee A, Poewe W, Litvan I (2000) Progression of Hoehn and Yahr stages in Parkinsonian disorders: a clinicopathologic study. Neurology 55: 888–891
Myslobodsky M, Lalonde FM, Hicks L (2001) Are patients with Parkinson’s disease suicidal? J Geriatr Psychiatry Neurol 14: 120–124
Olanow CW, Watts RL, Koller WC (2001) An algorithm (decision tree) for the management of Parkinson’s disease: treatment guidelines. Neurology 56 (Suppl 5)
Palmer CS, Schmier JK, Snyder E, Scott B (2000) Patient preferences and utilities for “off-time” outcomes in the treatment of Parkinson’s disease. Quality of Life Res 9: 819–827
Parkinson Study Group (2000) Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 284: 1931–1938
Parkinson Study Group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287: 1653–1661
Poewe W, Seppi K (2001) Treatment options for depression and psychosis in Parkinson’s disease. J Neurol 248 (Suppl 3): 12–21
Poewe WH, Wenning GK (1996) The natural history of Parkinson’s disease. Neurology 47 (Suppl 3): S146–152
Pollak P, Fraix V, Krack P, Moro E, Mendes A, Chabardes S, Koudsie A, Benabid AL (2002) Treatment results: Parkinson’s disease. Mov Disord 17 (Suppl 3): S75–83
Rascol 0, Brooks DJ, Korczyn AD, DeDeyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. NEJM 342: 1484–1491
Rascol 0, Goetz C, Koller W, Poewe W, Sampaio C (2002) Treatment interventions for Parkinson’s disease: an evidence based assessment. Lancet 359: 1589–1598
Schrag A, Jahanshahi M, Quinn N (2000) How does Parkinson’s disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 15: 1112–1118
Watts RL, Mirra SS, Richardson EP (1994) Corticobasal ganglionic degheneration. In: Marsden CD, Fahn S (eds) Movement Disorders. Butterworths-Heinemann, London
Wenning GK, Michlmayr S, Braune S, Brüke T, Fogel W, Gerster P, Schulz JB, Volkmann J (2001) Empfehlungen zur Differenzialdiagnose von Parkinson-Syndromen. Akt Neurol 28: 256–260
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Lachenmayer, L. (2003). Parkinson-Syndrom:Lebenserwartung und Lebensqualität — Realität versus Patientensicht. In: Przuntek, H., Müller, T. (eds) Morbus Parkinson. Steinkopff, Heidelberg. https://doi.org/10.1007/978-3-642-57362-0_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-57362-0_5
Publisher Name: Steinkopff, Heidelberg
Print ISBN: 978-3-7985-1422-5
Online ISBN: 978-3-642-57362-0
eBook Packages: Springer Book Archive